Background Oral contraceptives are rarely prescribed for women with systemic lupus
erythematosus, because of concern about potential negative side effects. In this double-blind, …

Background: There is concern that exogenous female hormones may worsen disease activity
in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of …

Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is
ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed …

Background and aims We studied damage accrual and factors determining development
and progression of damage in an international cohort of systemic lupus erythematosus (SLE) …

Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE
inception cohort. Methods. Patients in the Systemic Lupus International Collaborating Clinics …

… Kalunian and Davis contributed equally to this study. … Kalunian and Davis contributed
equally to this study. … Kalunian and Davis contributed equally to this study. …

Background Patients with systemic lupus erythematosus have substantial unmet medical
need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we …

Objectives To examine the safety and efficacy of rontalizumab, a humanised IgG1 anti-interferon
α (anti-IFN-α) monoclonal antibody, in patients with moderate-to-severe systemic lupus …

Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I interferon …

Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …